BCL2 and nervous system cancer: Although OFM lacks specific immunohistochemical markers, IHC is useful for excluding other myxoid lesions—S-100 helps rule out neural tumours, while CD34, STAT6, and BCL2 assist in excluding myxoid solitary fibrous tumour [14,15].